Reforgene wins Best Biopharmaceutical Company of the Year in the healthcare investment awards

On April 3, 2022, Haoyue Capital, a well-known investment bank in China's healthcare industry, officially released the "2022 Sixth Healthcare Investment Excellence List". Reforgene won the "Biopharmaceutical Company of the Year" award. A total of 15 biomedical technology enterprises nationwide were selected in this evaluation.

Reforgene is a leading innovative gene medicine enterprise in China, driven by gene editing technology and dedicated to the birth of novel medicines. It is worth noting that over the past year, Reforgene has also received multiple honors in selection activities hosted by well-known biomedical industry media and institutions, including the 2021 Biopharma Value List "Cell & Gene Therapy TOP10", the 2021 Most Investment-Worthy Emerging BioTech TOP5, and the 2021 China Top 10 Medical Innovation Enterprises, among others.

About the list

As a highly recognized annual authoritative list in the industry, the Healthcare Investment Excellence List has, since its first release in 2017, upheld the principles of fairness, impartiality and objective neutrality. Through the form of real-name voting with "authoritative judges, one vote each", based on publicly disclosed materials and information submitted by various institutions, it comprehensively reviews indicators such as the investment activity, transaction volume, transaction amount and investment returns of healthcare investment funds, and selects the outstanding investment institutions of the year. At the same time, the Excellence List also grants awards to outstanding healthcare enterprises in different fields such as biomedicine, innovative medical devices, in vitro diagnostics, medical services and smart healthcare, aiming to create a truly credible and influential investment list, set new benchmarks for industry development, and create new opportunities for investment cooperation.